{"generic":"Sodium Glycerophosphate","drugs":["Glycophos","Sodium Glycerophosphate"],"mono":{"0":{"id":"jrxis0","title":"Generic Names","mono":"Sodium Glycerophosphate"},"1":{"id":"jrxis1","title":"Dosing and Indications","sub":{"0":{"id":"jrxis1b4","title":"Adult Dosing","mono":"<ul><li>during the critical shortage of phosphate injection in the United States, the US Food and Drug Administration has authorized the importation and distribution of Glycophos(TM) sodium glycerophosphate sterile concentrate; call Fresenius Kabi USA Customer Service at 1-888-386-1300 for product availability and ordering.<\/li><li>1 mL of sodium glycerophosphate contains 1 mmol of phosphate and 2 mmol (2 mEq) of sodium<\/li><li><b>Intravenous feeding of patient, Supplement for phosphate requirements:<\/b> individualize; recommended dosage during IV nutrition is 10 to 20 mmol per day<\/li><\/ul>"},"1":{"id":"jrxis1b5","title":"Pediatric Dosing","mono":"<ul><li>during the critical shortage of phosphate injection in the United States, the US Food and Drug Administration has authorized the importation and distribution of Glycophos(TM) sodium glycerophosphate sterile concentrate; call Fresenius Kabi USA Customer Service at 1-888-386-1300 for product availability and ordering<\/li><li>1 mL of sodium glycerophosphate contains 1 mmol of phosphate and 2 mmol (2 mEq) of sodium<\/li><li><b>Intravenous feeding of patient, Supplement for phosphate requirements:<\/b> (infant and neonates) individualize; recommended dosage during IV nutrition 1 to 1.5 mmol\/kg\/day<\/li><\/ul>"},"3":{"id":"jrxis1b7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><br\/>Intravenous feeding of patient, Supplement for phosphate requirements<br\/>"}}},"3":{"id":"jrxis3","title":"Contraindications\/Warnings","sub":[{"id":"jrxis3b9","title":"Contraindications","mono":"<ul><li>dehydration<\/li><li>hypernatremia or hyperphosphatemia<\/li><li>renal insufficiency, severe<\/li><li>shock<\/li><\/ul>"},{"id":"jrxis3b10","title":"Precautions","mono":"renal function, impaired; monitoring recommended <br\/>"},{"id":"jrxis3b11","title":"Pregnancy Category","mono":"Unknown<br\/>"},{"id":"jrxis3b12","title":"Breast Feeding","mono":"Unknown<br\/>"}]},"5":{"id":"jrxis5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Other:<\/b>Absence of drug reaction<br\/>"},"6":{"id":"jrxis6","title":"Drug Name Info","sub":{"0":{"id":"jrxis6b17","title":"US Trade Names","mono":"Glycophos<br\/>"},"3":{"id":"jrxis6b20","title":"Regulatory Status","mono":"RX<br\/>"}}},"9":{"id":"jrxis9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>vials are preservative-free; intended for single-use only<\/li><li>must dilute in high-volume infusion fluids and infuse over 8 hours or more; complete infusion within 24 hours<\/li><\/ul>"}}}